You are here

Home » Content

BÖBREK TRANSPLANTASYONU YAPILMIŞ BİR OLGUDA TACROLIMUS (FK506) KULLANIMINA BAĞLI GEÇİCİ İNSÜLİNE BAĞIMLI DİABETES MELLİTUS GELİŞİMİ

Journal Name:

  • İstanbul Tıp Fakültesi Dergisi

Publication Year:

  • 2000

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Transient insuline dependent diabetes mellitus dııe to the use of tacrolimus (FK 506) in a renal transplant patient. Tacrolimus (FK506) is a new İmmunosupressive drug using in pri-mary immunosupressive treatment of solid organ transpiantation. One of the adverse effects of tacrolimus is insuline dependent diabetes mellitus (IDDM). We aimed to report a 20 years old, male patient who had been performed a uonrelatcd donor kidney transpiantation and to discuss the diabetogenic effects of tacrolimus therapy in children. At the 9th month of the transpiantation when hc was receiving triple immunosupressive therapy with tacrolimus, mycophenolate and prednisolone, gîucosuria and hyperglicemia were deteeted in the patient, and blood glucose levels inereased up to 550 mg/dl. Tacrolimus was discontinued, and insuline therapy was started at a dose of 1 U/kg/day. He dıd not necessiate insuline after an one month duration, and immunosupressive therapy was continued with eyelosporin A. Consequently, renal transplanted patients who use tacrolimus shoud be monitorcd carefully from the aspects of the risk of IDDM development.
Bookmark/Search this post with
Abstract (Original Language): 
Tacrolimus (FK506) solid organ transplantasyonu sonrası primer immunosupressif tedavide kullanılan yeni bir immunosupressif ilaçtır. İstenmeyen etkilerinden biri insuline bağımlı dia-betes mellitus (İBDM) gelişimidir. Bu olgu sunumunda, kiİniğimizde izlenen, 20 yaşında Aî-port sendromuna bağlı kronik böbrek yetmezliği nedeniyle 9 ay önce yurtdışında akraba dışı canlı donörden böbrek nakli olmuş ve böbrek transplantasyonu sonrası izlem sirasında tacrolimus kullanımına bağlı geçici diabetes meîlitus gelişmiş bir erkek hastanın sunulması ve ilacın bu istenmeyen etkisinin tartışılması amaçlanmıştır. Olgumuzda daha önce yurt dışmda başlanmış olan prednizolon, mycophenolate, tacrolimus İle üçlü immunsupressif tedavi sürmekte iken, transplantasyonun 9. ayında olguda hiperglisemi ve glikozun saplanmış, kan glukozu giderek yükselerek 550 mg/dl olmuştur. Tacrolimus kesilip, 1 ünite/kg/gün kristalize insülin başlandıktan sonra, bir ay içinde olgunun insülin gereksinimi kalmamış ve immunosupresif tedavisi siklosporin A ile sürdürülmüştür. Halen graft fonksiyonu stabil olarak devam etmektedir. Sonuç olarak, tacrolimus kullanan rcnal transplant olgular İBDM gelişimi açısından çok yakın izlenmeyi gerektirmektedir.
FULL TEXT (PDF): 
PDF icon arastirmax-bobrek-transplantasyonu-yapilmis-bir-olguda-tacrolimus-fk506-kullanimina-bagli-gecici-insuline-bagimli-diabetes-mellitus-gelisimi.pdf
  • 1
78-79
  • Turkish

REFERENCES

References: 

1. Krensky AM: Transpiantation Immunobİology. In Baratt TM, Avner EL, Harmon WE Pediatric Nephrology. İb-urth edİEion, Lippincott Wiliams { Wilkins 1999:1298
2. Bredow MA, Ehrich JH: Transient diabetes mellitus and peripheral insülin resistance foİlowing Tacrolimus into-xication in a child after renal transpiantation. Ncphrol Dial Transplant 1997; 12: 334-6.
3. Maycr AD, Dimitrewski J, Squifflel JP, Besse T, Gra-bensee B, Klein B, el al: Multicenter randomized Irial comparing tacrolimus (FK506) and cyclosporine in the prevenlion of rena! allograft rejection: a report of the Eu-ropean Tacrolimus Multicenter Renal Study Group. Transpiantation 1997 15; 64 (3):436-43.
4. McKce M, Segev D, Wise B, Case B, Nen A, Fivush B, Colombani P: Initial expericnce wiîh FK506 (tacrolimus) in pediatric renal transplant recipients. J Pediatr Surg 1997; 32:688-90.
5. Moxey-Mims MM, Kay C, Light JA, Kher KK: lncrea-sed incidence of insulin-dependent diabetes mellilus in pediatric renal transplant patients receiving tacrolimus (FK506). Transpiantation 1998; 65:617-9.
Bilge I., Öktem F . , Baş F . , Şirin A., Emre S., Nayır A.
6. Furth S, Neu A, Colombani P, Plotnick L, Turner M E, Fivush B: Diabetes as a complication of tacrolimus (FK506) in pediatric renal transplant patients. Pediatr Nephrol 1996; 10:64-6.
7. Drachenberg CB, Klassen DK, Weir MR, Wiland A, Fink JC, Bartlett ST, et al: islet celi damage associated with tacroliııuıs and cyclosporine: morphological fcatu-res in pancreas allograft biopsies and clinical correlation. Transpiantation 1999; 68{3): 396-402.
8. Shapiro R: Tacrolimus in pediatric renal transpiantation: a review. Pediatr Transplant 1998; 2(4): 270-6.
9. Krentz AJ, Dmitıewski J, Mayer D: Postoperative gluco-se metabolism in liver transplant recipients. Transpiantation 1994; 57(11): 1666-9.
10. Furth S, Neu A, Colombani P, Plotnick L, Turner ME, Fivush B: Diabetes as a complication of tacrolimus (FK506) in pediatric renal transplant patients. Pediatr Nepluoi 1996; 10(l):64-6.

Thank you for copying data from http://www.arastirmax.com